Deal snapshot: Lilly to Acquire POINT Biopharma in Transaction Valued at USD 1.4bn.

MANews-(C)2009-2023

US-based pharmaceutical company Eli Lilly and Company (NYSE: LLY) has agreed to acquire radiopharmaceutical company POINT Biopharma Global, Inc. (NASDAQ: PNT), with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer, the company said.

Lilly will commence a tender offer to acquire all outstanding shares of POINT for a purchase price of USD 12.50 per...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT